- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZD8895 | COV2-2196 | Evusheld® (tixagevimab + cilgavimab)
tixagevimab is an approved drug (EMA (2022))
Compound class: Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 . It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised . AstraZeneca have reported that Evusheld® retains neutralising activity against the omicron (B.1.1.529) SARS-CoV-2 variant.
1. Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P et al.. (2021)
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
Nat Microbiol, 6 (10): 1233-1244. [PMID:34548634]
2. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS et al.. (2020)
Potently neutralizing and protective human antibodies against SARS-CoV-2.
Nature, 584 (7821): 443-449. [PMID:32668443]